Biohaven Ltd. (BHVN)
NYSE: BHVN · Real-Time Price · USD
36.91
-2.86 (-7.19%)
Feb 21, 2025, 4:00 PM EST - Market closed
Biohaven Employees
Biohaven had 239 employees as of December 31, 2023. The number of employees increased by 37 or 18.32% compared to the previous year.
Employees
239
Change (1Y)
37
Growth (1Y)
18.32%
Revenue / Employee
n/a
Profits / Employee
-$3,365,418
Market Cap
3.73B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 239 | 37 | 18.32% |
| Dec 31, 2022 | 202 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
BHVN News
- 10 days ago - Biohaven: NDA Review Of Troriluzole Isn't Only 2025 Catalyst On Deck - Seeking Alpha
- 11 days ago - Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia - PRNewsWire
- 5 weeks ago - Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective Lowering of Galactose-Deficient IgA1 with Next Generation Potential Therapy for IgA Nephropathy - PRNewsWire
- 6 weeks ago - Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 2 months ago - Biohaven Advances in Immunotherapy: Significant IgG Reduction Achieved with BHV-1300, Gains Analyst Approval - Benzinga
- 2 months ago - Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates - PRNewsWire
- 2 months ago - Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual Meeting - PRNewsWire
- 3 months ago - Biohaven's Revenue Path: SCA And Obesity Therapies - Seeking Alpha